These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 38338677)

  • 1. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.
    Frumento D; Grossi G; Falesiedi M; Musumeci F; Carbone A; Schenone S
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule tyrosine kinase inhibitors in glioblastoma.
    Kim G; Ko YT
    Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping cancer in its tracks: using small molecular inhibitors to target glioblastoma migrating cells.
    Mattox AK; Li J; Adamson DC
    Curr Drug Discov Technol; 2012 Dec; 9(4):294-304. PubMed ID: 22339073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
    Bhusare N; Kumar M
    Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
    Raizer JJ
    J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment.
    Berro A; Assi A; Farhat M; Hatoum L; Saad JP; Mohanna R; Bechara AMA; Prince G; Hachem MCR; Zalaquett Z; Kourie HR
    Crit Rev Oncol Hematol; 2024 Jun; 198():104365. PubMed ID: 38677355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
    Zhou A
    Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel 1,3,4-thiadiazole derivatives as anti-glioblastoma agents targeting the AKT pathway.
    Szeliga M; Karpińska M; Rola R; Niewiadomy A
    Bioorg Chem; 2020 Dec; 105():104362. PubMed ID: 33074121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion.
    Rybin MJ; Laverde-Paz MJ; Suter RK; Affer M; Ayad NG; Feng Y; Zeier Z
    Bioorg Med Chem Lett; 2022 Apr; 61():128614. PubMed ID: 35151865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant
    Al-Ghabkari A; Huang B; Park M
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
    Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
    Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview.
    Baglini E; Chiaverini L; Tolbatov I; Taliani S; Da Settimo F; La Mendola D; Barresi E; Marzo T
    Biometals; 2024 Apr; 37(2):275-288. PubMed ID: 37930483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Development of Glioblastoma Therapeutic Agents.
    Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
    Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery.
    Brar HK; Jose J; Wu Z; Sharma M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.
    Yuan J; Zhang F; Hallahan D; Zhang Z; He L; Wu LG; You M; Yang Q
    J Exp Clin Cancer Res; 2018 Aug; 37(1):181. PubMed ID: 30071868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.